Skip to main
TRLV

TRLV Stock Forecast & Price Target

TRLV Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trulieve Cannabis is a well-positioned vertically integrated cannabis company with a dominant market share in Florida and strong growth opportunities in Georgia, Pennsylvania, and Texas. The company's strong financial performance, with 2Q26 EBITDA of $98M, SG&A of $102M, and revenue of $271M, highlights its ability to execute and maintain profitability in its core markets. In addition to its current success, Trulieve also has multiple potential catalysts, including federal regulatory reform and potential adult-use legalization in various states, that could further drive growth and profitability.

Bears say

Trulieve Cannabis is facing numerous headwinds that may negatively impact its future growth potential. These include delayed regulatory approvals, a restrictive regulatory framework in Alabama, and relatively limited growth opportunities in West Virginia. Furthermore, while Trulieve has a strong foothold in Florida's medical-only market and is expanding into other states, it faces competition in these markets and may face challenges in gaining regulatory approval. These factors could limit earnings growth and result in a lower valuation for Harvest, which Trulieve is planning to reconsolidate.

TRLV has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trulieve Cannabis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trulieve Cannabis Corp (TRLV) Forecast

Analysts have given TRLV a Buy based on their latest research and market trends.

According to 1 analysts, TRLV has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trulieve Cannabis Corp (TRLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.